As reported, pertuzumab blocks HER dimerization, by binding the dimerization domain of the HER2 receptor (ECD II), and also prevents ligand-induced dimerization of HER2 with HER3 inhibiting tumor growth [16–18]. Here, ERBB3 is linked to neoplasm.